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84 Poster Session Iengrafted slowly, after Day 42, perhaps related to some underlying
marrow dysfunction caused byMDS. Four patients developed acute
GvHD grades II-IV with a cumulative incidence at 100 Days of
16.7% (95% CI 1.4%-32.0%). Four patients relapsed with a CI of
relapse at 3 years of 15.0% (95% CI 0.0%-31.5%). Cumulative in-
cidence of non-relapse mortality at 1 year was 26.1% (95% CI
7.7%-44.5%). Nine pts died: 4 of infections (2 EBV, 1 adenovirus,
1 toxoplasmosis), 2 of graft failure, 2 of relapse, and 1 of MSOF.
Overall survival probability at 1 and 3 years were 70.4% (95% CI
51.9%-88.8%) and 59.5% (95% CI 38.7%-80.4%) respectively.
Event-free survival (EFS) probabilities at 1 and 3 years were
70.8% (95%CI 52.6%-89.0%) and 59.9% (39.2%-80.7%), respec-
tively. Factors associated with better EFS were age# 10 years (p5
0.03) and weight # 38 kg (p 5 0.02). These results, especially in
younger patients with Monosomy 7 and MDS, are equivalent to
matched allogeneic bone marrow transplant data. UCB should be
actively considered for pediatric MDS patients lacking matched re-
lated or unrelated adult donors.225
THE ADDITION OF ETOPOSIDE TO Bu16/Cy200 IN THE CONDITIONING
OF CHILDREN WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IS ASSOCIATED
WITH IMPROVED SURVIVAL
Ayas, M.1, Al-Mahr, M.1, Al-Jefri, A.1, Al-Seraihi, A.1, Belgaumi, A.1,
Al-Ahmari, A.1, El-Hassan, I.2, El-Solh, H.1. 1King Faisal Specialist
Hospital & Research Center, Riyadh, Saudi Arabia; 2King Faisal Special-
ist Hospital & Research Center, Riyadh, Saudi Arabia.
Relapse remains the major concern for children with AML un-
dergoing SCT, and we have previously shown that intensifying
the conditioning by adding etoposide at 60mg/kg and consequently
reducing the busulfan (Bu) dose to 12mg/kg and the cytoxan (Cy) to
90 mg/kg did not result in any significant improvement of the sur-
vival; we suggested then that the reduction of Bu/Cy doses necessi-
tated by addition of the high dose of etoposide could have affected
the outcome and we hypothesized that adding a lower dose of eto-
poside and keeping the Bu/Cy at the conventional doses may offer
better survival to AML patients undergoing allogeneic SCT. We
present here our results using such a protocol.
Patients andMethods: FromMarch 2003 until December 2006,
33 patients with AML (24 in CR1, 8 in CR 2) underwent allogeneic
SCT and were conditioned with Bu 16 mg/kg po, Cy 200 mg/kg iv
plus etoposide 900 mg/m2 iv, median age was 9.6 years. This cohort
of patients (group B) was compared with 18 AMLpatients (17 in CR
1, 1 in CR 2) who underwent SCT from July 93 thru February 96,
median age at SCT was 7.25 years, patients were conditioned with
only Bu 16 mg/kg po and Cy 200 mg/kg iv (group A).Results:Me-
dian days to ANC$ 500  106/l was 21 days and 15 days in groups
A and B respectively, median days to platelet count$ 20 109/l was
22 days and 26 days in groups A and B respectively (P5 NS). The
incidence of complications was similar, acute GVHD grade 2 or
higher developed in 5% and 9% in groups A and B respectively
(P5 NS), hemorrhagic cystitis developed in 11% and 15% in
groups A and B respectively, no VOD developed in either group.
The 4 year overall survival for groups A and B respectively was
50% and 68.2% (P 5 0.3) and the 4 year event-free survival for
groups A and B respectively was 33% and 68.2% (P5 0.1).Conclu-
sions: The addition of etoposide to Bu16/Cy200 was not associated
with increased toxicity, and although it did not reach statistical sig-
nificance, it does appear to be associated with a better overall and
event-free survival. Larger scale studies are advised to further cor-
roborate our findings.226
SINGLE DAILY DOSE (SDD) BUSULFAN (BU) IN CHILDREN: COMPARI-
SON OF PHARMACOKINETICS (PK) AND ENGRAFTMENT BETWEEN
ACUTE LEUKAEMIA (AL) AND NON MALIGNANT DISEASE (NM)
Shaw, P.J.1,3, Nath, C.E.2, Earl, J.W.2. 1Children’s Hospital at West-
mead, Sydney, NSW, Australia; 2Children’s Hospital at Westmead, Syd-
ney, NSW, Australia; 3University of Sydney, Sydney, NSW, Australia.Methods:We studied BU PK, engraftment and survival in chil-
dren who underwent allogenic BMT for NM (n 5 33) or AL (n 5
41) after BU-based conditioning. The dose of oral BU was 4 mg/kg
(n5 16) or 150 mg/m2 (n 5 32) and intravenous (IV) 3.2 mg/kg (n
5 3), 120 mg/m2 (n5 3) or 130 mg/m2 (n5 20). In 62 cases, blood
was collected after the first dose, BU levels were measured and BU
area-under-the-concentration-versus-time curve (AUC) was deter-
mined using the Kinetica software (Innaphase, USA), then normal-
ized to 130 mg/m2 for IV BU and 150 mg/m2 for oral BU. PK-
guided dose adjustments were made in 7 patients with NM. Total
exposure to BU was determined by dividing first dose AUC by first
dose (mg) and thenmultiplying by the total dose (mg) administered.
Results: In the NM group, 26(79%) are still alive. 5 (of 7) deaths
occurred early (\118 d post BMT) due to transplant-related causes:
VOD (1), VOD and GVHD (2), GVHD (1) and sepsis (1). Full en-
graftment was achieved in all but 5 patients (85%): 2 had stable
mixed chimerism (MC) .95% donor, 3 had inadequate engraft-
ment; 4 of these were part of a group of 12 who hadT cell depletion.
Total Bu exposure ranged from 57 to 146 mg/L.h (median 90 mg/
L.h). In the AL group, 29 (71%) are still alive, with 4 early trans-
plant-related deaths from GVHD (2), relapse (1) and sepsis (1).
Full engraftment was achieved in all but 3 patients (93%): 2 children
had MC and one of these subsequently lost the graft, another was
fully donor but died prior to obtaining full haematological recovery.
Total Bu exposure ranged from 40 to 345 mg/L.h (median 99 mg/
L.h). Results of the normalised AUC (nAUC) in mg/L.h are shown
in the table. nAUC was significantly higher in the oral BU group (n
5 36) than in the IV BU group (n5 26): 276 6mg/L.h versus 236
8 mg/L.h, p\0.01.Conclusions: Single daily dose BU is generally
safe and effective for use in children with AL andNM. A dose of 130
mg/m2 IV gives less exposure than 150mg/m2 oral.Wide variability
in BU pharmacokinetics indicates a need for measurement and per-
haps targeting in some patients, especially those with immune defi-
ciencies or those more likely to reject.normalised AUC (nAUC) mg/L.h
Diagnosis: Genetic SCID non-SCID ALIV Bu
nAUC (range) 20–44 14–50 18–31 14–30
median 23 16 21 18
fold variation 2.2 3.6 1.9 2.2
n 6 3 7 10Oral Bu
nAUC (range) 15–38 18–25 27–36 15–43
median 25 25 30 28
fold variation 2.5 1.4 1.3 2.9
n 9 3 4 20227
FUNGAL INFECTIONS: A SURVEY OF PEDIATRIC SURVEY OF PEDIATRIC
BLOOD & MARROW TRANSPLANT CONSORTIUM INSTITUTIONS
Fisher, V.L.1, Olson, E.A.2. 1Rainbow Babies & Children’s Hospital,
Cleveland, OH; 2Children’s Healthcare of Atlanta, Atlanta, GA.
This survey was designed to identify the fungal infectionmanage-
ment used for the pediatric BMT patient and to develop a standard
of care for fungal infection management by institutions within the
Pediatric Blood & Marrow Transplant Consortium (PBMTC).
Twenty five percent of the surveys were returned. 100%of the in-
stitutions performed allogeneic and autologous transplants. Non-
myeloablative transplants were performed by 89% of the institu-
tions.
All institutions used some type of fungal prophylaxis during
transplant, 77% used fungal prophylaxis on all their transplant pa-
tients. 50% of the centers differed on the prophylaxis used in the
BMT sub-groups, with 85% of the centers using Fluconazole,
and 15% of the institutions using no prophylaxis in autologous pa-
tients. 100% of centers administered prophylaxis to the allogeneic
transplant group. The break down of agents utilized in the allo-graft
group was Fluconazole (47%), Voriconazole (23%) and low dose
Poster Session I 85daily amphotericin (31%). Fungal prophylaxis was started pre-
transplant at 85% of the institutions, day 11 (15%) of the institu-
tions. Fungal prophylaxis was stopped with immunosuppressive
therapy at 69% of the centers, day 121 (7%), day 1100 (7%) and
17% of reporting institutions did not specify. Ninety-three percent
of the institutions used prophylaxis for cGVHD patients.
Fifty-percent routinely screen for fungal infections after day 0 in
both autologous and allogeneic transplants, utilizing weekly culture
surveillance (23%), fever only (25%), fever/clinical evidence (45%)
and by Glactamann assay (7%). Fungal organisms screened for in-
cluded Canididia (53%), Histoplasma (31%), Crytpotococcus
(15%), Aspergillus (85%), Zygomyces (45%) and Fusarium (31%).
The majority reported using hepa-filtered rooms and hand wash-
ing. N-95 masks (31%) were part of BMT isolation policy and 11%
used gowns. There were age specific visitor restrictions at 50% of
the institutions with no visitors under an age range of 12 to15 years
old.
Based on the submitted surveys the PBMTC institutions employ
various fungalmanagement practices. These findings suggest a need
to develop a fungal management standard of care for the pediatric
BMT patient. Further exploration of practices and outcomes is
needed to expand evidence based fungal management practices in
the pediatric BMT patient.228
RESOLUTION OF IPEX AND ACHIEVEMENT OF COMPLETE DONOR
CD31CD41 T-CELL ENGRAFTMENT FOLLOWING A REDUCED INTEN-
SITY CONDITIONING REGIMEN AND INFUSION OF A T- AND B-LYMPHO-
CYTE DEPLETED ALLOGENEIC BONE MARROW GRAFT
Wichlan, D.G.1, Shurtleff, S.A.2, Riberdy, J.M.1, Kasow, K.A.3. 1St.
Jude Children’s Research Hospital, Memphis, TN; 2St. Jude Children’s
Research, Memphis, TN; 3St. Jude Children’s Research, Memphis, TN.
Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome (IPEX) is a rare autoimmune disease, historically
resulting in death by 2 years of age. IPEX is characterized by muta-
tions in FOXP3, resulting in aberrant function of CD41CD25bright
regulatory T cells (Treg). Treg are critical regulators of immune
responses and dysfunctional activity results in unchecked im-
mune-mediated disease. Allogeneic hematopoietic stem cell trans-
plantation (HSCT) is the only potential cure, yet traditional
myeloablative conditioning, tends to be detrimental to this popula-
tion. Our patient, who has a FOXP3 missense mutation at 1150
G.A, presented with severe enteropathy, failure to thrive, psoriasi-
form dermatitis, and sepsis in early infancy. Prior to HSCT at 8
months of age, he developed autoimmune hemolytic anemia while
receiving immunosuppressive therapy. For HSCT, he received a
reduced intensity conditioning (RIC) regimen consisting of
Campath-1H, fludarabine, thiotepa, and melphalan, followed by
a T- and B-cell depleted matched unrelated donor bone marrow
graft with 5  106 CD31 cells/kg added back to facilitate engraft-
ment. Cyclosporine was continued for graft-versus-host disease
prophylaxis. Due to his severe enteropathy he received palifermin
3 days prior to beginning RIC and 3 days after HSCT. Condition-
ing and stem cell infusion were well tolerated. The patient achieved
myeloid engraftment (ANC . 500/mm3) on day 113 and platelet
engraftment (.50,000/mm3) on day 137. He reveals no clinical
signs of IPEX, including resolution of enteropathy and reduction
in serum IgE from 299 International units (IU)/ml to 4 IU/ml at
day 127; this marker remains within normal limits. Initial periph-
eral blood chimerism by VNTR analysis was 100%, yet decreased
over time, leading to the discontinuation of cyclosporine on day
191. To determine presence of Treg, myeloid and lymphocyte sub-
sets were purified by cell-sorting and analyzed by VNTR when cell
populations were . 10,000 cells. Well-defined CD31CD41 and
CD31CD81 T-cell populations were . 89% donor, with the
Treg population being 98% donor. Myeloid and NK cells and B
lymphocytes exhibit mixed chimerism 5 months after HSCT. Lym-
phocyte responses to mitogens were normal at day 1152. In sum-
mary, we have demonstrated that a child with IPEX can tolerate
HSCT with a RIC regimen and a T- and B-cell depleted graft
with minimal toxicity and achieve full Treg lymphocyte engraft-
ment in the presence of a mixed donor chimerism.229
TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (Bu) X 4 DAYS IN CHIL-
DREN UNDERGOING A REDUCED-INTENSITY CONDITIONING (RIC)
REGIMEN WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (AlloHSCT) IS SAFE ANDWELL-TOLERATED BUT RESULTS
IN SIGNIFICANTLY INCREASED Bu CLEARANCE (CL) AND DECREASED
AREA UNDER THE CURVE (AUC) AND HALF-LIFE (t1/2) WHEN COM-
PARED TO IV BU TWICE-DAILY DOSING PHARMACOKINETICS (PK) IN
ADULTS
Waxman, I.1, Bhatia, M.1, Milone, M.2, Shaw, L.M.2, Baldinger, L.1,
Militano, O.1, Garvin, J.1, George, D.1, Bradley, M.B.1, Satwani, P.1,
Schwartz, J.1, Wolownik, K.1, Foley, S.1, Hawks, R.1, Jin, Z.Z.1,
Baxter-Lowe, L.A.3, van de Ven, C.1, Cairo, M.S.1. 1Columbia Univer-
sity, New York, NY; 2University of Pennsylvania, Philadelphia, PA;
3UCSF, San Francisco, CA.
Inaccurate Bu dosing duringHSCTconditioning can result in in-
creased graft failure or excessive regimen-related toxicity. IV Bu is
safe and effective in pediatric HSCT recipients at a dose of 4 mg/
kg/day (#4 yr) or 3.2 mg/kg/day (.4 yr) using q6 h  16 dosing
but Bu PK is age-dependent (Wall, Blood, 2000a). Q12 h  8 dos-
ing has been shown to be safe and effective in adults, withmean first-
dose AUC 3576 mmol*min, t1/2 3.46 h and CL 1.88 ml/min/kg
(Fernandez, BBMT, 2002). However, Bu safety and PK data is lack-
ing for q12 h  8 dosing in pediatric HSCT recipients. We studied
15 pediatric pts, mean age 9.5 yr (1.4–20.9 yr) with malignant (n 5
5) and nonmalignant (n 5 10) conditions who underwent RIC for
alloHSCT with IV Bu q12 h  8 dosing (4 mg/kg/day [\ 4 yr];
3.2 mg/kg/day [$4 yr]), fludarabine (30 mg/m2/day  5 days) and
alemtuzumab (54 mg/m2/5 days). Phenytoin/fosphenytoin load
was given prior to start of Bu; maintenance continued 48 h post-
Bu. Donor sources were: 3 6/6 & 1 5/6 matched-related donor, 1
10/10, 2 9/10 & 2 8/10 MUD, 2 6/6 related cord blood (CB) and
4 4/6 unrelated CB. PK samples (n 5 12) were obtained at hr 1,
2, 3, 5, 6, 7 and 8 after start of 1st dose. Bu levels were measured
by a GC-MS method on heparinized plasma. Results are summa-
rized in Table I. Target Css was 600–900 ng/ml. 5 pts required
dose increases; 1 was dose-reduced. Mean CL (ml/min/kg) for\4
yr (n 5 3) was significantly higher than in $4 yr (4.59 6 0.52 v
3.45 6 0.72, p 5 .0326). Difference between mean Bu t1/2 for\4
yr v $4 yr trended toward but did not reach significance (1.94 h
6 0.46 v 2.57 h6 0.59, p5 0.13). 2 pts (13%) had seizures unrelated
to Bu; there was no VOD. Donor chimerism was 80% at D1 30 (n
5 13) and 90% at D 1 60 (n 5 11). 1 of 15 pts had primary graft
failure; this pt also had the 2nd highest Bu CL (4.77 ml/min/kg),
lowest t1/2 (1.62 h) and 2nd lowest AUC (1648 mmol*min). In sum-
mary, we demonstrated significantly lower AUC and t1/2 and signif-
icantly increased CL when compared to adult q12h dosing PK data,
suggesting that q12h IV Bu PK may depend on patient age (Table
I).We also found a significant age-dependent (\4 yr v$4 yr) differ-
ence in Bu CL, possibly due to increased glutathione-S-transferase
activity (Gibbs, Drug Metab Dispos, 1999). Furthermore, we
showed that q12h IV Bu in pediatric pts results in low toxicity
and high engraftment post-RIC regimen. Additional pediatric sub-
jects are needed to determine if increased Bu CL and decreased
AUC result in increased risk of graft failure.Busulfan pharmacokinetic data for q12 hour dosing in pediatric and adult
patients
AUC mmol*min t1⁄2 , hr CL, ml/min/kg Vd, L Css ng/ml(mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD)Pediatric
(n 5 12;
n 5 11 for
AUC & VD1900 ± 383 2.41 ± 0.61 3.74 ± 0.83 22.8 ± 14.6 653 ± 125Adult (n 5 6)
(Fernandez,
BBMT,
2002)3576 ± 740 3.46 ± 0.38 1.88 ± 0.37 Not
ReportedNot
Reportedp-value p\.0001 p5.0015 p5.0001 NA NA
